Tag: DCGI
Applications for grant of NOCs for BA/BE studies made ‘online only’...
As a part of its e-governance initiatives, the clinical research regulator will accept only online application from 13 September 2016 for issue of NOCs.....
On its way back to revival, Indian clinical research industry awaits...
There used to be a time when India was an instant hit globally for its affordable yet quality expertize in handling clinical trials but then.....
India to soon launch its indigenously developed vaccine against Leprosy
Developed by Dr G P Talwar, Founding Director of National Institute of Immunology, this exclusive vaccine for leprosy will be piloted in five districts....
AIMED welcomes govt’s advisory on domestic standards for procuring medical devices
The association of Indian medical devices industry has stated that the move will create fair parity between domestically......
Industry welcomes CDSCO’s circular on investigators & sites
The Central Drugs Standard Control Organization's decision reflects the views of most of the stakeholders, mentioned the Indian Society for.......
Quintiles welcomes DCGI’s revised rules on clinical trials
In a statement, one of the leading global players in clinical research has appreciated the move by the Drugs Controller General.....
DCGI revises its 50 bed hospital, 3 clinical trials per investigator...
The Drug Controller General of India has finally decided to revise the earlier move that made maximum 3 trials per investigator....
Biocon registers strong performance, profits up by 17%
Biocon in the first quarter of the financial year 2016-17, has reported the revenues of Rs 952 crore; net profit up by 17 percent at Rs 147 crore ....
Revised ‘India specific’ biosimilar guidelines expected soon
While the 'Biosimilar Guidelines' adopted in 2012 have been well appreciated, there was an overall sentiment ...
Will try to ensure new therapeutics reach patients at earliest, says...
Dr G N Singh, Drug Controller General of India (DCGI) has sought cooperation from all the stakeholders...